Extracellular Matrix Proteins as Early Markers in Diabetic Nephropathy by Jäckle-Meyer, Irmtrud et al.
Jackie-Meyer et al: Renal extracellular matrix protein excretion in diabetic nephropathy 211
Eur J Clin Chem Clin Biochem
1995; 33:211-219
© 1995 Walter de Gruyter & Co.
Berlin · New York
Extracellular Matrix Proteins as Early Markers in Diabetic Nephropathy1)
By Irmtrud Jackie-Meyer1, Borika Szukics\ Kerstin Neubauer1, Vera Metze1, R diger Petzoldt2 and Hilmar Stalte1
1
 Arbeitsbereich Experimentelle Nephrolog)>, Abteilungf r Nephrologie, Zentrum fiir Innere Medizin und Dermato-
logie, Medizinische Hochschule Hannover, Hannover, Germany
2
 Herz- und Kreislaufzentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany
(Received June 2, 1994/January 31, 1995)
Summary: Basement membrane thickening and mesangial expansion characterize the renal involvement in
diabetes mellitus and precede any symptoms of renal dysfunction, e. g., albuminuria and changes in glomerular
filtration rate. Since the morphological changes can only be diagnosed by biopsy, this study was designed to
investigate whether the urinary excretion of renal extracellular matrix proteins might reflect the morphologi-
cal alterations.
To specify the extent of renal involvement in diabetes, the patients, type I as well as type II diabetics, were classified
according to their urinary albumin excretion: normal albumin excretion below 30 μg/min, microalbuminuria from
30 to 300 μg/min, and overt albuminuria above 200 μg/min. Laminin, collagen IV, and fibronectin, all intrinsic
components of the renal extracellular matrix, were determined in serum and urine by radioimmunoassay or enzyme-
linked-immunosorbent-assay, respectively. The results are given as median values (x). Additionally, the urinary
fragment pattern of fibronectin was analysed qualitatively by immunoblotting.
Laminin concentrations in serum and in urine did not change in diabetics. Collagen IV decreased in serum of
patients with increased albumin excretion (controls: χ = 255 μg/l, normoalbuminuric patients: χ = 56 μg/lJ microal-
buminuric patients: χ = 52 μg/l, and patients with overt albuminuria: χ = 70 μg/l; α < 0.01) and increased in
urine (controls, normoalbuminuric and microalbuminuric patients: not detectable, patients with overt albuminuria:
χ = 5 ng/12 h; α < 0.001). Fibronectin was elevated in serum (controls: χ = 355 mg/1; normoalbuminuric patients:
χ = 640 mg/1, microalbuminuric patients: χ = 710 mg/1, and patients with overt albuminuria: χ = 630 mg/1;
α < 0.0001) and in urine, even in patients with normal albumin excretion (controls: χ = 16.8 μg/12 h, normoalbum-
inuric patients: x = 121 μg/12h, microalbuminuric patients: x = 108μg/12h, patients with overt albuminuria:
χ = 186 \ig/l2 h; α < 0.01). The urinary fragment pattern of fibronectin, consisting of two main bands of a relative
molecular mass of Mr 75000 and 45000, was not altered in controls and diabetics. Type I and type II diabetic
patients did not show significant differences in any quantities tested.
It was shown in this study that the determination of laminin and collagen IV in serum and urine gave no
information exceeding the routinely used quantities of kidney function. But the renal fibronectin excretion was
elevated before any functional changes occurred. It was concluded that this might be indicative of the early
mesangial expansion in diabetes mellitus. The determination of urinary fibronectin could therefore probably
serve as a more sensitive marker for renal involvement in diabetes mellitus than microalbuminuria or changes
in glomerular filtration rate.
]) Supported by the Deutsche Forschungsgemeinschaft Sto 71/6-1 in the framework of the programme STEP (Science and Technol-
and Sto 71/6-2 and the Commission of the European Community ogy of Environment Protection).
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Introduction
About 45% of type I diabetic patients develop overt dia-
betic nephropathy in the course of their disease. One
quarter of all new cases of uraemia are due to this dia-
betic complication (1). These facts underscore the neces-
sity of carefully monitoring kidney function in diabetic
patients. Microalburninuria is currently the first sign that
may indicate an incipient diabetic nephropathy. Approxi-
mately 80% of younger diabetic patients and 20% of
elder patients with microalbuminuria progress to overt
'diabetic nephropathy (2). However, before microalbu-
minuria can be diagnosed, morphological alterations in
the kidney, such as basement membrane thickening and
mesangial expansion, occur (3). Maurer et al. (4) de-
monstrated that mesangial expansion especially corre-
lates with the clinical manifestation of diabetic nephro-
pathy.
The morphological alterations are due to changes in the
metabolism, composition and integrity of the renal extra-
cellular matrix induced by the metabolic disorders in di-
abetes (5). It was demonstrated that in mild to moderate
diabetic nephropathy laminin, collagen IV, and fibronec-
tin accumulate in the glomerular extracellular matrix
(6—8), while the amount of these structural proteins
within the glomerular apparatus is drastically reduced in
the advanced stage of the disease coinciding with glo-
merular sclerosis (6, 7). Further, the decrease of sul-
phated proteoglycans in the glomerular basement mem-
brane in diabetes leads to the loss of the charge selectiv-
ity, and consequently to glomerular proteinuria (9).
To date, the morphological alterations can only be diag-
nosed by biopsy and subsequent immunohistochemistry
or electronmicroscopy. Since these methods are not indi-
cated in monitoring the state of the kidney in diabetic
patients, the question arises whether the changes in the
renal extracellular matrix might be reflected by an al-
tered excretion of the relevant proteins in final urine.
Little is known about the urinary excretion of structural
proteins. Weil et al. (10) described a decreased excretion
of "glomerular basement membrane-like protein" in the
urine of diabetic rats. Mellon et al. (11) and Torffvit et
al. (12) found an increased collagen IV excretion in con-
genitally diabetic mice and in men with progressing al-
bumin excretion, respectively.
Therefore, the aim of the present study was to investi-
gate the relevance of the urinary excretion of extracellu-
lar matrix proteins, especially in the early phases of re-
nal involvement in diabetes mellitus. Collagen IV, lami-
nin, and fibronectin as the major intrinsic components of
the glomerular basement membrane and the mesangial
matrix were determined in the urine of type I and type II
diabetic patients without any symptoms of diabetic ne-
phropathy and at different stages of this disease.
Patients and Methods
Subjects
In this trial 86 in-patients of a Diabetes Hospital with type I diabe-
tes (insulin-dependent; n = 34) and type II diabetes (non-insulin
dependent, n = 52) were examined. To be included in this study,
the patients had to have a known history of diabetic nephropathy
or no symptoms of renal involvement in diabetes. Subjects with a
renal disease different from diabetic nephropathy, benign or malig-
nant tumours, inflammatory processes, recent surgery, and pregnant
women were excluded from this study. The detailed clinical data
on the patients are listed in table 1. Type I diabetics received insulin
injections. Nineteen type II diabetics were treated with oral sulpho-
nylurea antidiabetics (glibenclamide, Euglucon®; glipizide, Gli-
benese®), 18 with insulin, 10 with a combination of both, while 5
had no therapy with antidiabetic agents.
Twenty-one normotensive, healthy volunteers (10 males, 11 fe-
males) ranging in age from 23 to 81 years served as control per-
sons.
From each patient and from the healthy control persons 12-hours
urine specimens were collected (8:00 p.m. to 8:00 a.m.). Addi-
tional serum samples were obtained after overnight fasting. Ali-
quots of serum and urine were combined with ΙΟμΙ proteinase
inhibitor solution per ml sample (0.1 mol/1 phenyl-methyUsulpho^
nyl-fluoride in dimethylsulphoxide; Sigma Chemicals, St. Louis,
MO, USA) and stored at -20 °C for further use.
Quantities measured in general
Endogenous creatinine clearance was determined by measuring se-
rum and urine creatinine with an automated creatinine analyzer
(Model R2, Beckman Instruments GmbH, Munich, Germany). Glu-
cose was analysed with a commercially available test kit (Boeh-
ringer, Mannheim, Germany) and total urinary protein according
to Bradford (13). Urinary albumin was determined by rocket-im-
muno-electrophoresis (14).. Anti-human-albumin antibodies and
purified human albumin were purchased from Behring Werke AG
(Marburg, Germany). HbAic was measured as described by Cole
etal. (15).
Tab. 1 Clinical data on the diabetic patients (medians and ranges)
No. of patients
Age (a)
Diabetes duration
(a)
Blood glucose
(mmol/1)
HbAic (%)
Systolic blood
pressure (mmHg)
Diastolic blood
pressure (mmHg)
Retinopathy
Neuropathy
Angiopathy
Type]
34
40
15
8.4
10.1
120
70
21
10
2
[
(20/14)
(18-83)
(0-44)
(1.5-22.0)
(7.0-14.5)
(100-180)
(60-110)
Type II
52
51
13
7.2
11.3
125
80
14
9
3
(27/25)
(32-80)
(1-41)
(2.2-19.9)
(6.4-14.3)
(90-180)
(50-100)
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Quant i ta t ive determination of extracellular matrix
proteins
Laminin-Pl-fragment in serum and urine was quantified with a
commercially available radioimmuno-assay (Behring Werke AG,
Marburg, Germany).
Collagen IV in serum and urine was analysed by a sandwich-en-
zyme-linked-immunosorbent-assay. Specific antibodies were raised
in rabbits against human placental collagen IV (Sigma chemicals,
St. Louis, MO, USA) and purified by affinity chromatography on
Protein-A-Sepharose (Pharmacia-LKB, Uppsala, Sweden). To
measure collagen IV concentrations, high affinity flat-bottom
microtitre plates (Greiner, N rtingen, Germany) were coated with
anti-collagen IV antibodies, diluted 1 :200 in coating buffer (15
mmol/1 Na2CO3, 35 mmol/1 NaHCO3, 0.3 mol/1 NaN3, pH 9.6), at
+ 4 °C overnight. Remaining free binding sites on the plastic sur-
face were blocked with 2 g/1 bovine serum albumin in phosphate
buffered saline (0.15 mmol/1 NaCl, 8 mol/1 Na2HPO4, 3 mmol/1
KC1, 1.5 mmol/1 KH2PO4, 0.3 mol/1 NaN3, 0.5 ml/1 Tween 20, pH
7.4). Thereafter, urine and serum samples were incubated in paral-
lel with the collagen IV standards (human placental collagen IV;
Sigma Chemicals, St. Louis, MO, USA) in a serial dilution from
1 to 2500 μg/l in phosphate buffered saline. Bound antigens were
detected with the same anti-collagen IV antibody used in the first
step, but now coupled to alkaline phosphatase (dilution 1 : 1000 in
phosphate buffered saline). Visualization of the bound antibody
was achieved by the enzymatic reaction of alkaline phosphatase
with 1 g/1 /7-nitrophenylphosphate (Sigma Chemicals, St. Louis,
MO, USA) in substrate buffer (1 mol/1 diethanolamine, 0.5 mmol/1
MgCl2 X 6 H2O, pH 9.8). The concentration of the coloured reac-
tion product was measured at 405 nm (Titertek Multiskan Photome-
ter, Flow Laboratories, McLean, VA, USA). Between each incuba-
tion step microtitre plates were rinsed 5 times with phosphate buf-
fered saline (Titertek Microplate Washer S8/12, Flow Laboratories,
McLean, VA, USA). Alkaline phosphatase (Type VII from bovine
intestinal mucosa; Sigma Chemicals, St. Louis, MO, USA) was
conjugated to the antibodies by the one-step glutaraldehyde method
described by Avrameas (16).
The inter-assay coefficient was 12% and the intra-assay coefficient
was 10%. Cross reactions with other collagen types and structural
proteins such as laminin and fibronectin could not be observed.
Total fibronectin was determined with a sandwich-enzyme-Iinked-
immunosorbent-assay (17). Anti-human plasma fibronectin was
purchased from Dako AS (Copenhagen, Denmark) and purified
human plasma fibronectin from Sigma Chemicals (St. Louis, MO,
USA). Conjugation of alkaline phosphatase to the antirfibronectin
antibody was also performed as described by Avrameas (16).
Immunoblott ing of fibronectin
The urinary proteins were separated in a 5—16% sodium dodecyl-
sulphate-polyacrylamide gradient gel prior to the blotting pro-
cedure. Slabgels were prepared on GelBond PAG films (125 X 260
mm; Pharmacia LKB, Uppsala, Sweden), in a gel casting chamber,
125 X 260 X 0.5 mm (Pharmacia LKB, Uppsala, Sweden). The
running gel was prepared of equal volumes of dense acrylamide
solution (160 g/1 acrylamide, 3 g/I bis-acrylamide; 170 g/I sucrose,
1 g/1 sodium dodecylsulphate, 0.4 ml/1 tetramethylene diamine, 0.4
g/1 ammonium persulphate in 0.4 mol/1 Tris HC1 buffer, pH 8.6),
and light solution (50 g/1 acrylamide, 2 g/1 bis-acrylamide; 1 g/1
sodium dodecylsulphate, 0.4 ml/1 tetramethylene diamine, 0.4 g/1
ammonium persulphate in 0.4 rnol/1 Tris HC1 buffer, pH 8.6),
mixed with a gradient former. The stacking gel was composed as
follows: 50 g/1 acrylamide, 0.2 g/1 bis-acrylamide, 0.8 g/l sodium
dodecylsulphate, 0.8 ml/1 tetramethylene diamine, 0.8 g/1 ammo-
nium persulphate in 0.06 mol/1 Tris HC1 buffer, pH 6.8.
Samples were combined with equal volumes of sample buffer (10
ml/1 glycerol, 20 g/1 sodium dodecylsulphate, 10 ml/1 rnercapto-
ethanol in 75 mmol/I Tris HC1 buffer, pH 6.8). They were heated
at 95 °C for 10 min, alkylated with 10 g/1 iodoacetic acid, and
heated again for 20 min at 95 °C. Bromophenol blue was used as
front marker. Molecular mass standard (biotinylated SDS-PAGE
standard, low range and high range, Biorad, Richmond, CA, USA)
and purified plasma fibronectin were run in parallel.
A buffer containing 25 mmol/1 Tris HC1, and 200 rnmol/J glycine,
pH 8.6, was used for electrophoresis, which was performed in a
Multiphor II Electrophoresis Unit (Pharmacia LKB, Uppsala, Swe-
den) at + 5 °C for 30 min at 20 mA and then for 2.5 h at 30 mA.
Proteins were transferred onto nitrocellulase (Transfer Membrane
Immobilon P, pore size 0.45 μπι; Millipore Corporation, Bedford,
MA, USA) after electrophoresis by semidry-blotting (Sartoblot-II-
S, Sartorius, G ttingen, Germany) in a discontinuous buffer system
(18). The protein transfer was performed at 1.5 m A/cm2 for 45
min. Thereafter, nitrocellulose was incubated in 20 g/1 casein in
phosphate buffered saline (140 mmol/1 NaCl, 1.5 mmol/1 KH2PO4,
10 mmol/1 Na2HPO4, 2.5 mmol/1 KC1, 0.3 mol/1 NaN3, pH 8.2) for
1 hour at 37 °C. The immunologic reactions were performed with
appropriate antibodies diluted in 2 g/1 casein, and 0.5 ml/1 Tween
20 in phosphate buffered saline. The following detection system
was used for the detection of urinary fibronectin: anti-human-fibro-
nectin-antibodies (diluted 1 :4000; incubation: 1 hour at 37 °C),
biotinylated anti-rabbit-IgG-antibodies (diluted 1 :2000: incuba-
tion: 1 hour at 37 °C), streptavidin coupled to alkaline phosphatase
(diluted 1 : 2000; incubation: 1 hour at 37 °C). All antibodies were
purchased from Dako AS (Copenhagen, Denmark). Nitrocellulose
was rinsed five times for 5 min with phosphate buffered saline
between each incubation step. The bound antibodies were visual-
ized by the enzymatic reaction of the coupled alkaline phosphatase
as described by Blake et al. (19).
Statistical analysis
For statistical analysis, the correlation coefficient was determined
and the Mann-Wlrifney test for independent samples was used. The
level of significance was defined as α = 0.05.
Results
Quantities measured in general
Currently, the determination of the urinary albumin
excretion is the best method to identify patients with a
high risk of diabetic nephropathy, since microalbumin-
uria (urinary albumin excretion > 20—70 μg/min) is
predictive of the development of this diabetic complica-
tion. The aim of the present study was to evaluate
whether the urinary excretion of extracellular matrix
proteins gives additional information about the renal in-
volvement in diabetes. The diabetic patients included in
this study were therefore grouped according to their uri-
nary albumin excretion. Diabetics with normal urinary
albumin excretion below 30 μg/min, with microalbu-
minuria (urinary albumin excretion 30—200 μg/min),
and with overt albuminuria (urinary albumin excretion
above 200 μg/min) were differentiated. In table 2 the
functional quantities such as creatinine clearance, total
urinary protein excretion, and urinary albumin excretion
determined for the patients and the control persons are
given. With regard to these quantities no significant dif-
ferences between type I and type II diabetics could be
found within the three groups of diabetics.
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Tab. 2 Functional quantities of the diabetic patients and of the controls (median and ranges).
The di(Terences between type I and type II diabetic patients are not significant in the different groups.
Creatinine clearance
(ml/min X 1.73 m2)
Total urinary protein
(mg/12 h)
Urinary albumin
(mg/12 h)
Controls (n = 21) 109(85-168)
Diabetic patients with normal albumin excretion (< 30 μg/min)
All (n = 46) 110(81-166)
Type I (n=17) 117(85-166)
Type II (n = 29) 104(81-140)
31.2 (1.5-52.5)
33.8 (14.4-75.2)
35.0 (14.4-53.0)
38.7 (20.1-75.2)
Diabetic patients with microalbuminuria (urinary albumin excretion 30-200 μ§/ηιίη)
All (n = 20) 80(17-127) 81.5 (48.5-507)
Type I (n= 7) 109(36-127) 144.3 (58.8-507)
Typell (n = 13) 72(17-112) 81.7 (48.5-192)
5.53 (0.56-16.92)
7.17 (0.9 -21.11)
7.44 (1.21-19.95)
7.17 (0.9 -21.11)
39.95 (22 -132.5)
39.1 (24.3-123.2)
39.6 (22 -132.5)
Diabetic patients with overt
All
Type I
Type II
(n =
(n =
<n =
20)
10)
10)
albuminuria (urinary albumin excretion > 200 μ§/πιίη)
60(16-175)
81 (27-175)
54(16- 82)
557
556
1080
(26-5782)
(26-6782)
(114-3908)
446
628
546
(118-5273)
(289-1925)
(188-5273)
As intrinsic components of the renal extracellular matrix
laminin, collagen IV, and fibronectin were determined
in serum and in urine of the patients and the healthy
controls. Since none of the quantities tested were dif-
ferent in type I and type II diabetic patients, the results
for the two groups are presented together.
Laminin
The serum concentration and the urinary excretion of
laminin was determined. It can be seen that the serum
concentrations (fig. la) and the urinary excretion (fig.
Ib) of this extracellular matrix protein did not change
with the progression of renal involvement in diabetes as
monitored by the urinary albumin excretion. Further,
both quantities were also unaltered in comparison to the
control group.
Collagen IV
Serum concentration of collagen IV (fig. 2a) was dimin-
ished in all diabetic patients compared to the control
persons (a < 0.01).
The urinary excretion of collagen IV is shown in figure
2b. No detectable amounts of collagen IV could be
found in the urine of the control group, whereas 2% of
the normoalbuminuric diabetics, 45% of the microalbu-
minuric, and 50% of the macroalbuminuric patients
excreted detectable amounts of collagen IV. The controls
and the patients with normal albumin excretion showed
no significant difference in collagen IV excretion, while
the patients with microalbuminuria and with overt albu-
minuria excreted significantly higher amounts of this
protein (a < 0.001).
Serum concentrations and urinary excretion of collagen
IV did not correlate to other quantities such as duration
of diabetes, HbAlc, creatinine clearance, urinary excre-
tion of protein and albumin.
Fibronectin
Serum fibronectin was elevated in all diabetic patients
(a < 0.0001; fig. 3a). The determination of urinary fi-
bronectin showed an increased excretion in all diabetic
patients compared to the control group (a < 0.001; fig.
3b). Serum concentration and urinary excretion of fibro^
nectin did not correlate to the duration of diabetes,
HbAIC, creatinine clearance, urinary excretion of protein
and albumin, and urinary excretion of collagen IV.
To investigate whether the elevated urinary excretion of
fibronectin is accompanied by alterations of the pattern
of the breakdown products of fibronectin found in urine,
additional qualitative studies in the urine by immu-
noblotting were performed. It was shown that fibronec-
tin was excreted in a distinct, recurrent fragment pattern
consisting of two main proteins bands with an apparent
relative molecular mass of MT 75000, and 45000
(fig. 4). The fragment pattern was similar in controls and
in diabetic patients, independent of the stage of renal
involvement in diabetes, and of the type of diabetes. This
demonstrates the existence of a very early quantitative
but no qualitative change in urinary fibronectin excreted
in diabetic patients.
Discussion
Diabetes induces morphological alterations in the kid-
ney, such as glomerular basement membrane thickening
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and expansion of the mesangial matrix, which occurs
prior to albuminuria and changes of glomerular filtration
rate (2, 20). Methods based on the measurement of these
functional quantities, routinely used in the diagnosis of
diabetic nephropathy, lack the sensitivity required for
early detection of the above mentioned structural
changes, because the kidney has considerable functional
reserves (21). To date, basement membrane thickening
and mesangial expansion can only be diagnosed by bi-
opsy, which is not indicated to monitor the renal in-
volvement in diabetes. Therefore, this study was de-
signed to evaluate whether the urinary excretion of ex-
tracellular matrix components in diabetic patients might
be able to reflect the alterations in renal morphology and
the underlying biochemical processes.
Type I as well as type II diabetic patients were included
in this study because both groups are affected by dia-
betic nephropathy (5, 22-24). Since the two groups did
not differ significantly with regard to the quantities mea-
sured in general, no distinction was made between them
in the following discussion.
The extent of renal involvement in diabetes was speci-
fied by the urinary albumin excretion since microalbu-
minuria is currently the most sensitive marker and pre-
dictive for the development of diabetic nephropathy (2).
Laminin, collagen IV, and fibronectin were determined
since these proteins are principal components of the re-
nal extracellular matrix.
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Laminin, measured as laminin PI-fragment, is predomi-
nantly localized at the endothelial site of the laminae
rarae, where it is responsible for cell attachment and
probably contributes, besides the proteoglycans, to the
charge selectivity of the basement membrane (25, 26).
Immunohistochemical studies by Falk et al. (6) showed
an increase of laminin in the glomerular and tubular
basement membrane, and in the mesangial matrix in
early and moderate diabetic nephropathy, whereas the
content of this protein was decreased in severe nephro-
pathy. Shimomura et al. (27) and Karttunen et al. (28)
found a decreased laminin concentration in the diabetic
basement membrane by biochemical methods. No sig-
nificant difference in serum laminin concentrations and
in the urinary excretion of this protein was found be-
tween the diabetic patients and the control persons in
this study. The slight increase of the lamiriin Pi-frag^·
ment in the serum of diabetic patients, as described by
Hoegemann et al. (29), could not be confirmed. The re-
sults of the present study indicatefthat the laminin con-
centration in serum and in urine is independent of the
stage of diabetic nephropathy, and that laminin excretion
in urine is not able to reflect the changes this protein
underlies in the diabetic kidney.
Collagen IV, which provides a resilient three-dimen-
sional network forming the backbone of the glomerular
basement membrane, is another important constituent of
the renal extracellular matrix determined in this study
(30-32). In the diabetic kidney, changes in the metabo-
lism of collagen IV are principally responsible for the
thickening of the glomerular basement membrane (6, 8,
33). The metabolic disorders lead to an increased synthe-
sis of this protein and further to a decreased degradation
which results in an accumulation of collagen IV in the
glomerular basement membrane (34-36). The determi-
nation of collagen IV in serum showed significantly de-
creased concentrations in the diabetic patients in cqm-
parison to controls. This is in contrast to findings of
others, who found an increased serum concentration of
collagen IV in diabetic patients (29, 37) or no alterations
(12). The decreased serum concentration of collagen
IV found in the present study is interpreted as a
consequence of the decreased degradation of this pro-
Mr
[103]
 1
220-
3 4
Fig. 4 Representative immunoblot of the urinary fragment pattern
of flbronection.
Lane 1: purified human plasma fibronectin,
lane 2: urine of a control person,
lane 3 :urine of a patient with normal albumin excretion (<30
μ§/ππη),
lane 4: urine of a patient with microalbuminuria (urinary excretion
n
 30-200 μ§/ηιίη),
lane 5: urine of a patient with overt albuminuria (urinary excretion
> 200 '
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tein in nearly all basement membranes. The urinary
excretion of collagen was significantly increased in
patients with microalbuminuria and with overt albu-
minuria. This is in agreement with findings of Torfjvit
et al. (12), who additionally found a decreased urinary
excretion of collagen IV in advanced diabetic nephro-
pathy. The results show that the determination of colla-
gen in urine is able to reflect the alterations of this
protein in the diabetic kidney. It is suggested that the
destruction of the glomerular basement membrane in
the course of the progressing glomerular sclerosis is
responsible for the elevated urinary excretion of this
protein. But since the collagen IV excretion raises in
parallel to the albumin excretion, its determination
in final urine yields no additional information to the
quantities routinely used.
Fibronectin, as an intrinsic component of the renal extra-
cellular matrix, was also determined. This protein is pre-
dominantly localized in the mesangial matrix (7, 26, 38).
It is produced by mesangial and endothelial cells as well
as by pericytes (39, 49, 41). Fibronectin found in the
glomerular basement membrane is supposed to be
trapped from plasma and not to be of renal origin (25,
30, 31). In diabetes an accumulation of fibronectin in
the mesangial matrix was shown in mild to moderate
diabetic nephropathy, while the content of this protein
was decreased in sclerotic glomeruli (6, 7).
In the present study fibronectin was increased in the se-
rum of all diabetic patients, even in those with normal
urinary albumin excretion. Other studies showed incon-
sistent results. Labat-Robert et al. (42) found a de-
creased plasma fibronectin concentration in diabetics
whereas Degiorgto et al. (43) reported increased concen-
tration in patients with retinopathy and microalbumin-
uria. Davis et al. (44) could not find any difference in
serum fibronectin content in diabetic and non-diabetic
persons.
The urinary fibronectin excretion was elevated prior to
the onset of microalbuminuria. This could coincide with
the accumulation of this protein in the mesangial matrix
in early and moderate diabetic nephropathy (6, 7) and,
thus, reflect the impaired fibronectin metabolism in the
diabetic kidney.
I
' Since the urinary excretion of fibronectin seems to be
valuable in assessing the early involvement of the
kidney in diabetes, it was studied not only quantita-
tively but also qualitatively by immunoblotting. The
protein was excreted in a distinct fragment pattern of
two main bands with an apparent relative molecular
mass of A/r 75 000, and 45 000 in the urine of control
persons and of diabetic patients at different stages
of nephropathy. The unaltered and recurring fragment
pattern indicates that these fragments are products of
a defined turnover of fibronectin in the kidney. Its
quantitatively elevated excretion in parallel to its
unchanged qualitative excretion suggests an inbalanced
turnover in diabetes.
Metabolic and micropuncture experiments in rats de-
monstrated that the urinary fibronectin fragments origi-
nate from the glomeruli and that the fragment pattern is
not altered during tubular passage. Serum fibronectin is
found in final urine only in cases of severe glomerular
damage, when high molecular mass plasma proteins are
allowed to permeate the glomerular filter (45, 46).
From the results of the present study the following cas-
cade of events is hypothesized. The accumulation of ex-
tracellular matrix proteins is probably due to the high
glucose concentration in the tissue, which is supposed
to stimulate the protein synthesis and to diminish the
protein degradation (48—50). The non-enzymatic glyca-
tion of the proteins, and the formation of oxygen radi-
cals are the suggested mechanisms through which glu-
cose causes these biochemical alterations (51—54). The
expanding mesangium, which compresses the capillary
vasculature and ultimately leads to glomerular closure,
is thought to be the primary cause for the development
of diabetic nephropathy rather than the loss of the charge
and size selectivity of the glomerular filtration barrier
(4, 55).
Conclusion
We show in this study that
(1) the changes laminin undergoes in diabetes are not
reflected by its urinary excretion,
(2) collagen IV excretion is elevated in parallel to the
occurrence of microalbuminuria and probably reflects
the decline of the glomerular basement membrane,
(3) urinary fibronectin is elevated in diabetic patients
prior to functional restrictions and probably reflects the
mesangial expansion due to the accumulation of extra-
cellular matrix proteins probably caused by increased
glucose concentration in the tissue.
With regard to these findings, urinary fibronectin excre-
tion may serve as an early marker for the renal involve-
ment in diabetes, but further studies are necessary to
substantiate this assumption.
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